NCT00001305View on ClinicalTrials.gov

Growth Hormone Therapy in Osteogenesis Imperfecta

PHASE3CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 5, 1991

Primary Completion Date

May 19, 2017

Study Completion Date

May 19, 2017

Conditions
Osteogenesis Imperfecta
Interventions
DRUG

Humatrope

Patients receive a subcutaneous injection.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

NCT00001305 - Growth Hormone Therapy in Osteogenesis Imperfecta | Biotech Hunter | Biotech Hunter